JP2014530852A5 - - Google Patents

Download PDF

Info

Publication number
JP2014530852A5
JP2014530852A5 JP2014537023A JP2014537023A JP2014530852A5 JP 2014530852 A5 JP2014530852 A5 JP 2014530852A5 JP 2014537023 A JP2014537023 A JP 2014537023A JP 2014537023 A JP2014537023 A JP 2014537023A JP 2014530852 A5 JP2014530852 A5 JP 2014530852A5
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
cancer
compound according
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014537023A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530852A (ja
JP6165748B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2012/000158 external-priority patent/WO2013058691A1/en
Publication of JP2014530852A publication Critical patent/JP2014530852A/ja
Publication of JP2014530852A5 publication Critical patent/JP2014530852A5/ja
Application granted granted Critical
Publication of JP6165748B2 publication Critical patent/JP6165748B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014537023A 2011-10-19 2012-10-15 脱ユビキチン活性の阻害方法 Expired - Fee Related JP6165748B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE1100776 2011-10-19
SE1100776-2 2011-10-19
SE1200303-4 2012-05-16
SE1200303 2012-05-16
PCT/SE2012/000158 WO2013058691A1 (en) 2011-10-19 2012-10-15 Method for inhibition of deubiquitinating activity

Publications (3)

Publication Number Publication Date
JP2014530852A JP2014530852A (ja) 2014-11-20
JP2014530852A5 true JP2014530852A5 (enExample) 2015-11-26
JP6165748B2 JP6165748B2 (ja) 2017-07-19

Family

ID=48141165

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014537023A Expired - Fee Related JP6165748B2 (ja) 2011-10-19 2012-10-15 脱ユビキチン活性の阻害方法

Country Status (21)

Country Link
US (1) US9221761B2 (enExample)
EP (1) EP2780326B1 (enExample)
JP (1) JP6165748B2 (enExample)
KR (1) KR102022575B1 (enExample)
CN (1) CN104271557B (enExample)
AU (1) AU2012326682B2 (enExample)
BR (1) BR112014009365B1 (enExample)
CA (1) CA2852518C (enExample)
CL (1) CL2014000998A1 (enExample)
DK (1) DK2780326T3 (enExample)
EA (1) EA026409B1 (enExample)
ES (1) ES2713484T3 (enExample)
HU (1) HUE041816T2 (enExample)
IL (1) IL232118A (enExample)
MX (1) MX345467B (enExample)
MY (1) MY169330A (enExample)
PL (1) PL2780326T3 (enExample)
PT (1) PT2780326T (enExample)
SG (1) SG11201401608PA (enExample)
WO (1) WO2013058691A1 (enExample)
ZA (1) ZA201403302B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2780326T (pt) * 2011-10-19 2019-03-04 Vivolux Ab Método para inibição da atividade da desubiquitinação
EP2938610A2 (en) 2012-12-28 2015-11-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
EP3164506A4 (en) * 2014-07-01 2018-02-28 Mayo Foundation for Medical Education and Research Methods and materials for identifying and treating mammals resistant to proteasome inhibitor treatments
GB201416754D0 (en) * 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
MY188957A (en) * 2015-03-30 2022-01-14 Mission Therapeutics Ltd 1-cyano-pyrrolidine compounds as usp30 inhibitors
CN106146542A (zh) * 2015-04-23 2016-11-23 北京大学 姜黄素硼酸衍生物,其制备方法和应用
GB201522768D0 (en) * 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
US10416163B2 (en) * 2016-02-26 2019-09-17 Regents Of The University Of Minnesota Method and treatment of recurring endometrial cancer with an inhibitor of USP14
WO2018140907A1 (en) * 2017-01-30 2018-08-02 Up Therapeutics Inc. Novel spiro and cyclic bis-benzylidine proteasome inhibitor for the treatment of cancer, diabetes and neurological disorders
US12539292B2 (en) 2018-04-01 2026-02-03 Arvinas Operations, Inc. BRM targeting compounds and associated methods of use
CN111956804B (zh) * 2020-07-21 2022-01-07 广州医科大学 Otub1的抑制剂的新应用
CN114959036A (zh) * 2022-06-07 2022-08-30 北京大学 Rpn11标记物在检测骨髓瘤及其患病风险、预后分析及治疗药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1242379A1 (en) * 1999-12-03 2002-09-25 Emory University Curcumin analogues for treating cancer
EP1572078A4 (en) * 2002-03-08 2006-08-09 Univ Emory NEW CURCUMINOID FACTOR VIIa CONSTRUCTS AS MEANS OF SUPPRESSING TUMOR GROWTH AND ANGIOGENESIS
US20070010488A1 (en) * 2005-04-13 2007-01-11 Khairia Youssef Compounds for modulating cell proliferation
ATE411300T1 (de) * 2005-08-05 2008-10-15 Hybrigenics Sa Neue cysteine protease hemmers und ihre therapeutische anwendungen
WO2007059613A1 (en) * 2005-11-22 2007-05-31 University Of Saskatchewan Antineoplastic compounds
CA2767808A1 (en) * 2009-07-06 2011-01-13 The Ohio State University Research Foundation Compositions and methods for inhibition of cancers
PT2780326T (pt) * 2011-10-19 2019-03-04 Vivolux Ab Método para inibição da atividade da desubiquitinação

Similar Documents

Publication Publication Date Title
JP2015501833A5 (enExample)
JP2017511360A5 (enExample)
JP2012516900A5 (enExample)
JP2013522212A5 (enExample)
JP2015505296A5 (enExample)
JP2012092149A5 (enExample)
JP2014500295A5 (enExample)
JP2011173928A5 (enExample)
JP2016534084A5 (enExample)
JP2015514808A5 (enExample)
JP2012067116A5 (enExample)
JP2012158602A5 (enExample)
US20090069394A1 (en) Cancer treatment with epothilones
JP2019507114A5 (enExample)
JP2016503399A5 (enExample)
WO2018122168A1 (en) Combinations of bub1 kinase and parp inhibitors
JP2015522033A5 (enExample)
KR20180013850A (ko) 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린의 용도
RU2016116789A (ru) Комбинация энзалутамида и афурезертиба для лечения рака
FI3383385T4 (fi) Melflufeeniannoskuureja syöpään
US20220118123A1 (en) Combination of ar antagonists and targeted thorium conjugates
JP2017516829A5 (enExample)
JP2013525290A5 (enExample)
WO2014210369A2 (en) Reversal of cysteine-inactivated neuromuscular blocking drugs with combinations of reversal agents
RU2016110546A (ru) Комбинированная лекарственная терапия